Association of gastric cancer risk with genetic variant of HRH 2

Georgijs Moisejevs, Linda Piekuse, Liene Ņikitina-Zaķe, Sergejs Isajevs, Armands Sivins, Guntis Ancans, Marcis Leja

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Introduction: Histamine H2 receptor (HRH2) has a crucial role in the regulation of gastric acid secretion and has an important role in the process of the gastric mucosa inflammation. SNP of HRH2 gene enhancer element promoter rs2607474 results in transition of -1018 G > A and may be associated with the changes of expression of the receptor. Currently only a few papers are published by the Arisawa group on the association of HRH2 SNP rs2607474 with gastric mucosa atrophy and gastric cancer in Japanese population [Arisawa et al., 2012; Yamada et al., 2012]. Study Aims: Is to find out if there is association of HRH2 -1018 G > A (rs2607474) genotype and gastric cancer in Latvian population. Methods: Gastric cancer patients (n = 121) and control patients (n = 650) from Latvia were included in the study. All gastric cancer patients had approved histopathological diagnosis by two expert pathologists. All control group patients underwent upper gastrointestinal tract endoscopy with the further histopathological evaluation. The local Committee of Ethics approved study protocol before patient recruitment was started. All the patients signed informed consent forms before the enrollment. Blood sample was taken from each patient for DNA extraction with further genotyping. Genotyping for rs2067474 (-1018 G > A) was performed with Taqman Probebased system (Applied Biosystems Inc., Carlsbad, CA, USA) using commercially available probe (C_15859301_10) on an automatic sequence detection instrument (Real-Time PCR System, Applied Biosystems Inc., Calrsbad, CA, USA). Results AG genotype was present in 1/121 gastric cancer patient and 20/650 control group patients. AA genotype was not present in gastric cancer group, neither among control group. Frequency of A allele in the gastric cancer group was 0.41% and in control group – 1.54% (p = 0.231). There was no significant difference comparing genotype ratios between two study groups (p = 0.228). After adjusting for gender, age and HP serology no significant difference in genotype frequency was identified (OR = 0.236, CI95% = 0.030–l.896, p = 0.l76).
Conclusions Our results suggest that HRH2 -1018 G > A (rs2607474) genotype in Latvian population is not associated with gastric cancer frequency. Further studies with larger study population are needed to check the hypothesis.
Original languageEnglish
Pages (from-to)86
Number of pages1
JournalCollection of Scientific Papers
Issue numberSuppl.1
Publication statusPublished - Dec 2015

Field of Science

  • 3.2 Clinical medicine
  • 3.1 Basic medicine

Publication Type

  • 3.4. Other publications in conference proceedings (including local)

Fingerprint

Dive into the research topics of 'Association of gastric cancer risk with genetic variant of HRH 2'. Together they form a unique fingerprint.

Cite this